Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)
-
Published:2024-01
Issue:1
Volume:9
Page:102196
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Incorvaia L.ORCID, Badalamenti G., Novo G., Gori S., Cortesi L., Brando C., Cinieri S., Curigliano G., Ricciardi G.R., Toss A., Chiari R., Berardi R., Ballatore Z.ORCID, Bono M.ORCID, Bazan Russo T.D., Gristina V., Galvano A., Damerino G., Blasi L., Bazan V., Russo A.
Subject
Cancer Research,Oncology
Reference45 articles.
1. BRCAness revisited;Lord;Nat Rev Cancer,2016 2. Hereditary breast and ovarian cancer: new genes in confined pathways;Nielsen;Nat Rev Cancer,2016 3. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers;Kuchenbaecker;J Am Med Assoc,2017 4. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing;Pujol;Eur J Cancer,2021 5. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies;Russo;ESMO Open,2022
|
|